Who
James Huang
Director
Company insider
Files Form 4 as: Director, Connect Biopharma Holdings; Director and 10% owner, Atara Biotherapeutics; Director, Alaunos Therapeutics; Director and 10% owner, Windtree Therapeutics; Director, CASI Pharmaceuticals.
In numbers
- Trades disclosed
- 70
- Buys
- 30
- Sells
- 1
- Bought
- $18.1M
- Sold
- $489K
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 30 May 2013
- Last trade
- 29 May 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 May 2026filed 2 Jun 2026 | CNTB Connect Biopharma HoldingsBiotechnology | SEC FORM 4 Bought | $372K150,000 at $2.48 | filing |
| 29 May 2026filed 2 Jun 2026 | CNTB Connect Biopharma HoldingsBiotechnology | SEC FORM 4 Bought | $372K150,000 at $2.48 | filing |
| 31 Mar 2026filed 1 Apr 2026 | CNTB Connect Biopharma HoldingsBiotechnology | SEC FORM 4 Bought | $4.0M1,160,000 at $3.45 | filing |
| 31 Mar 2026filed 1 Apr 2026 | CNTB Connect Biopharma HoldingsBiotechnology | SEC FORM 4 Bought | $4.0M1,160,000 at $3.45 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $489K80,554 at $6.07 | filing |
| 17 Jul 2025filed 21 Jul 2025 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $186K19,335 at $9.64 | filing |
| 6 Jun 2023filed 8 Jun 2023 | TCRT Alaunos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 22 Feb 2023filed 23 Feb 2023 | Windtree Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —275,862 at $0.00 | filing |
| 22 Feb 2023filed 23 Feb 2023 | Windtree Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —275,938 at $0.00 | filing |
| 22 Feb 2023filed 23 Feb 2023 | Windtree Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —498,008 at $0.00 | filing |
| 22 Feb 2023filed 23 Feb 2023 | Windtree Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —62,500 at $0.00 | filing |
| 22 Feb 2023filed 23 Feb 2023 | Windtree Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,112,308 at $0.00 | filing |
| 22 Feb 2023filed 23 Feb 2023 | Windtree Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code X | —1,112,308 at $0.00 | filing |
| 22 Feb 2023filed 23 Feb 2023 | Windtree Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,224,616 at $0.00 | filing |
| 22 Feb 2023filed 23 Feb 2023 | Windtree TherapeuticsBiotechnology | SEC FORM 4 Code X | $156K1,112,308 at $0.14 | filing |
| 8 Sep 2022filed 8 Sep 2022 | CASI Pharmaceuticals | SEC FORM 4 Bought | $143K33,300 at $4.28 | filing |
| 7 Sep 2022filed 8 Sep 2022 | CASI Pharmaceuticals | SEC FORM 4 Bought | $12K3,111 at $4.00 | filing |
| 6 Sep 2022filed 8 Sep 2022 | CASI Pharmaceuticals | SEC FORM 4 Bought | $75K19,162 at $3.89 | filing |
| 2 Sep 2022filed 2 Sep 2022 | CASI Pharmaceuticals | SEC FORM 4 Bought | $1,496400 at $3.74 | filing |
| 1 Sep 2022filed 2 Sep 2022 | CASI Pharmaceuticals | SEC FORM 4 Bought | $44K11,821 at $3.72 | filing |
News
Analyzing Connect Biopharma (NASDAQ:CNTB) & Dianthus Therapeutics (NASDAQ:DNTH)CNTB · tickerreport.com · 22 Oct 2026Contrasting Legend Biotech (NASDAQ:LEGN) & Connect Biopharma (NASDAQ:CNTB)CNTB · tickerreport.com · 13 Oct 2026Connect Biopharma's (CNTB) "Buy" Rating Reiterated at HC WainwrightCNTB · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name James Huang; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.